Join Medicenna for a live webinar featuring company management and KOLs Dr. Hussein A. Tawbi, MD, PhD (The University of Texas MD Anderson Cancer Center), and Dr. André Mansinho, MD, MSc (a Principal Investigator in the Phase 1/2 ABILITY-1 study, START Lisbon, Portugal, Gulbenkian Institute for Molecular Medicine).

The event will provide an overview of Medicenna’s global Phase 1/2 ABILITY-1 study of MDNA11. MDNA11 is an investigational, long-acting IL-2 Superkine designed to activate and expand cancer-fighting immune cells. ABILITY-1 is evaluating MDNA11 both as a monotherapy and in combination with Merck’s KEYTRUDA® (pembrolizumab). Management will also discuss updated data from ABILITY-1, which completed enrollment of 152 patients across North America, Europe, Australia and South Korea. The updated results will be presented by Prof. Paolo Ascierto in an oral session at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting on November 7, 2026, where the abstract was selected as one of the meeting’s Top 150 Abstracts. Dr. Tawbi and Dr. Mansinho will discuss the unmet need, the study design and the results to date. A live question and answer session will follow the formal presentations.